Exciting News in the World of Precision Oncology!

Aptose Biosciences Inc. Enters into Common Share Purchase Agreement

SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced it has entered into a common share purchase agreement and registration rights agreement with an institutional investor.

The Committed Equity Facility agreement provides Aptose the right, in its sole option and discretion without obligation, to sell and issue up to $25 million of its common shares (the “Common Shares”) over the course of 24 months to the Investor, subject to certain conditions being met, and subject to certain limitations and conditions imposed by the Nasdaq Capital Market (“Nasdaq”), the U.S. Securities and Exchange Commission (the “SEC”) and other regulators.

This is a significant development for Aptose as it secures funding for its groundbreaking precision oncology research and development efforts. The TUS-based triple drug frontline therapy being developed by Aptose has the potential to revolutionize the treatment of patients with newly diagnosed AML, offering hope and new possibilities for those battling this aggressive form of cancer.

How This Announcement Will Affect You

As a patient diagnosed with AML or any other form of cancer, this announcement brings hope for potentially more effective and targeted treatment options in the near future. Aptose’s innovative approach to precision oncology could lead to advancements in personalized medicine that may improve outcomes and quality of life for cancer patients.

How This Announcement Will Affect the World

The collaboration between Aptose Biosciences Inc. and the institutional investor underscores the growing interest and investment in precision oncology research and development. The potential success of Aptose’s TUS-based therapy could have a ripple effect in the field of oncology, paving the way for more targeted and effective treatments for a wide range of cancers.

Conclusion

Overall, the announcement of Aptose Biosciences Inc. entering into a common share purchase agreement is a promising development in the world of precision oncology. This collaboration has the potential to drive innovation, improve patient outcomes, and make a significant impact on the future of cancer treatment. Exciting times lie ahead in the fight against cancer!